AusBiotech says R&D Tax Incentive critical to 2030 Innovation Strategy


Preserving the R&D Tax Incentive will be top priority as AusBiotech coordinates comment for Innovation and Science Australia’s (ISA) consultation to develop a 2030 Strategic Plan for Australian innovation, science and its research system.

AusBiotech believes the destruction that will be caused if the proposed $2 million cap proceeds will seriously and immediately impact the ISA strategic plan.

AusBiotech members are invited to add comment to the industry’s submission as ISA seeks the views of key stakeholders to help develop the strategy in response to an Issues Paper.

The Issues Paper nominates six challenges that ISA sees as central to shaping the strategy, and suggests themes and questions for discussion.

ISA will develop the strategy to help guide the Government’s investment in the innovation system and recognises that there are many relevant reviews and studies that have been completed, on which it intends to build and current initiatives, including those under the National Innovation and Science Agenda (NISA).

ISA has already completed a review of the current performance of the system, which was released in February 2017 and can be found online.

Submissions are open until 31 May 2017 and AusBiotech members can direct comment by 28 May to Lorraine Chiroiu, Deputy CEO of AusBiotech ( / 03 9828 1414) or visit  for more information.